Clinical and microbiological characteristics of community-acquired pneumonia associated with \textit{Streptococcus pneumoniae} in adult patients in Mexico

Gabriela Echaniz-Aviles\textsuperscript{a}, Elvira Garza-González\textsuperscript{b}, Alma Lucía Román-Mancha\textsuperscript{c}, Rayo Morfin-Otero\textsuperscript{d}, Eduardo Rodríguez-Noriega\textsuperscript{d}, Juan Jacobo Ayala-Gaytán\textsuperscript{e}, Claudia Elena Guajardo-Lara\textsuperscript{e}, Araceli Soto-Nogueron\textsuperscript{a}, María Noemí Carnalla-Barajas\textsuperscript{a}, Adrián Camacho-Ortiz\textsuperscript{c,*}

\textsuperscript{a} Instituto Nacional de Salud Pública, Cuernavaca, Morelos, Mexico

\textsuperscript{b} Servicio de Gastroenterología y Departamento de Patología Clínica, Hospital Universitario "Dr. José Eleuterio González", Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico

\textsuperscript{c} Coordinación de Epidemiología Hospitalaria, Hospital Universitario "Dr. José Eleuterio González", Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico

\textsuperscript{d} Departamento de Infectología, Hospital Civil Fray Antonio Alcalde, e Instituto de Patología Infecciosa, Guadalajara, Jalisco, Mexico

\textsuperscript{e} Hospital San José Tec de Monterrey, Monterrey, Nuevo León, Mexico

Received 15 March 2018; accepted 9 October 2018
Available online 8 January 2019

**KEYWORDS**

*Streptococcus pneumoniae*; Vaccine; Serotype; Antimicrobial resistance

**Abstract** The aim of this study was to assess the risk factors and clinical and microbiological characteristics of community-acquired pneumonia (CAP) in adult patients in Mexico. *Streptococcus pneumoniae* classified as the causative agent of CAP in adult patients and patients with invasive *S. pneumoniae* isolates presented to three tertiary teaching hospitals during the 15-year study period were selected. Serotyping and susceptibility testing were performed for all included isolates. Clinical and demographic data were recorded. A total of 96 patients infected with *S. pneumoniae* (71 with CAP, 25 with invasive disease) were included. The CAP group involved more males (74.6%) than the invasive disease group (*p* = 0.03). Head trauma was more common in the CAP group (21.1%) than in the invasive disease group (4.0%; *p* = 0.03). The most prevalent serotype was 19A, followed by serotypes 3 and 23F. After the introduction of the heptavalent conjugated pneumococcal vaccine (PCV7), the prevalence of included serotypes declined significantly; no such change was found after the introduction of the PCV13 vaccine, including in the prevalence of serotype 19A. Susceptibility to all antimicrobials tested except vancomycin declined over the study period.

\textsuperscript{*} Corresponding author.

\textit{E-mail address: acamacho_md@yahoo.com} (A. Camacho-Ortiz).


0325-7541/© 2018 Published by Elsevier España, S.L.U. on behalf of Asociación Argentina de Microbiología. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introducción

Streptococcus pneumoniae es uno de los microorganismos más prevalentes en la población y en la comunidad, y su presencia se ha asociado con enfermedades respiratorias como la neumonía, las neumonías invasivas, la meningitis bacteriana o la otitis media. Esta asociación se debe a la virulencia intrínseca de la bacteria, a la presencia de una inmunidad materna y a la formación de colonias persistentes en el tracto respiratorio. Sin embargo, la resistencia de esta bacteria a los antimicrobianos está aumentando, lo que dificulta el tratamiento de las infecciones causadas por S. pneumoniae.

En México, se ha observado una alta prevalencia de S. pneumoniae en las neumonías invasivas, y se ha encontrado que la mayoría de las infecciones se producen en adultos mayores de 65 años. Esta situación se debe en parte a la disminución de la efectividad de la vacuna antineumocócica conjugada (PCV7) en México, lo que ha llevado a una mayor prevalencia de infecciones asociadas con serotipos de S. pneumoniae no cubiertos por la vacuna. En este contexto, la introducción de la vacuna antineumocócica conjugada de 13 serotipos (PCV13) ha sido crucial para prevenir las infecciones asociadas con S. pneumoniae.

En conclusión, la resistencia de S. pneumoniae a los antimicrobianos y la disminución de la efectividad de la vacuna antineumocócica conjugada han contribuido al aumento de las infecciones asociadas con S. pneumoniae en México. Es esencial implementar programas de vacunación de alta cobertura y monitorear la resistencia antimicrobiana para prevenir y controlar las infecciones causadas por S. pneumoniae.
need to describe the clinical and microbiological characteristics of CAP in adult patients in Mexico. This need is supported by the Mexican data requirement for the authorized introduction of PCV13 for adults. The aim of this study was to assess the risk factors, microbiology, and antibiotic resistance of CAP in adult patients in Mexico.

**Methods**

**Design, setting, and patients**

Data and samples from patients who presented to three tertiary care hospitals over a 15-year period (January 2000–September 2015) were included in this study. The institutions were the Hospital Universitario Dr. José Eleuterio González, a 500-bed public hospital in the city of Monterrey; the Hospital San José, Tec de Monterrey, a 220-bed private hospital; and the Hospital Civil Fray Antonio Alcalde de Guadalajara, a 1000-bed public hospital.

Cases with clinical and radiological evidence of CAP were detected through a retrospective review of all respiratory samples received from the microbiology laboratory of each hospital. Inclusion criteria were age ≥ 18 years, lower respiratory tract (LRT) sample obtained within 48 h of hospital admission, radiographic evidence of new infiltrate, and three or more of the following symptoms: dyspnea, hemoptysis, cough, sputum production, chest pain, fever, headache, and abnormalities on chest auscultation or percussion.

Only patients with radiological changes consistent with pneumonia radiology reports were included. Clinical data, including outcomes, comorbidities, and antibiotic prescriptions, were recovered retrospectively from the patients’ hospital records.

Patients with at least one positive *S. pneumoniae* culture and a clinical diagnosis of pneumonia were included. We also included patients with invasive disease for the comparison of clinical and microbiological data.

Clinically relevant non-invasive CAP isolates were defined as those from sputum, transtracheal aspiration, or bronchoalveolar lavage and others in which *S. pneumoniae* grew as a single or predominant colony. Sputum samples with >25 leukocytes and <10 epithelial cells per low-power field were processed. The clinical diagnosis of pneumonia was based on (a) positive *S. pneumoniae* culture, (b) positive radiographic findings, (c) and clinical data indicating pneumonia. Invasive isolates were isolated from blood, cerebrospinal fluid, pleural fluid, and ascites. Specimens were processed according to the guidelines described in the Clinical Microbiology Procedures Handbook.

Patients for whom clinical information was available were included. Sex, age, length of hospital stay, and overall mortality rate, as well as comorbidities and laboratory results, were analyzed. Two different periods were analyzed: the pre-PCV7 period considered from the year 2000 to 2007 and the post-PCV7–PCV13 period from 2008 to 2015.

This work was approved by the Ethical Committee of Universidad de Guadalajara.

---

**Table 1** Demographic and clinical characteristics of patients with pneumococcal diseases in Mexico

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Total n = 96</th>
<th>CAP (LRT Non-invasive isolates) n = 66</th>
<th>Invasive isolates n = 25</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Male, n (%)</strong></td>
<td>66 (68.7)</td>
<td>53 (74.6)</td>
<td>13 (52.0)</td>
<td>0.03</td>
</tr>
<tr>
<td><strong>Median age y (range)</strong></td>
<td>43 (94–14)</td>
<td>42 (94–14)</td>
<td>48 (80–16)</td>
<td>0.13</td>
</tr>
<tr>
<td><strong>LOS (days) (mean ± SD)</strong></td>
<td>10 (115–0)</td>
<td>11 (115–0)</td>
<td>8 (52–0)</td>
<td>0.32</td>
</tr>
<tr>
<td><strong>28-Day mortality, n (%)</strong></td>
<td>14 (14.58)</td>
<td>8 (11.26)</td>
<td>6 (24)</td>
<td>0.12</td>
</tr>
<tr>
<td><strong>Primarily medical diagnosis, n (%)</strong></td>
<td>65 (66.6)</td>
<td>44 (61.9)</td>
<td>20 (80.0)</td>
<td>0.16</td>
</tr>
<tr>
<td><strong>Comorbidities</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Diabetes, n (%)</strong></td>
<td>11 (15.5)</td>
<td>9 (12.6)</td>
<td>2 (8.0)</td>
<td>0.72</td>
</tr>
<tr>
<td><strong>HIV/AIDS, n (%)</strong></td>
<td>4 (4.1)</td>
<td>3 (4.2)</td>
<td>1 (4.0)</td>
<td>0.96</td>
</tr>
<tr>
<td><strong>Cancer, n (%)</strong></td>
<td>8 (8.3)</td>
<td>5 (7.0)</td>
<td>3 (12.0)</td>
<td>0.72</td>
</tr>
<tr>
<td><strong>Head trauma, n (%)</strong></td>
<td>16 (16.6)</td>
<td>15 (21.1)</td>
<td>1 (4.0)</td>
<td>0.03</td>
</tr>
<tr>
<td><strong>Renal insufficiency, n (%)</strong></td>
<td>3 (3.1)</td>
<td>3 (4.2)</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td><strong>Pregnancy, n (%)</strong></td>
<td>2 (2.0)</td>
<td>1 (1.4)</td>
<td>1 (4.0)</td>
<td>0.45</td>
</tr>
<tr>
<td><strong>Laboratory results (mean ± SD)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Hemoglobin (g/dl)</strong></td>
<td>12.12 (19.3–7.5)</td>
<td>11.9 (18–7.5)</td>
<td>12.8 (19.3–7.8)</td>
<td>0.21</td>
</tr>
<tr>
<td><strong>Leucocytes (mil/mm³)</strong></td>
<td>12.64 (37–2.4)</td>
<td>11.8 (34.8–2.4)</td>
<td>15.17 (37–2.56)</td>
<td>0.16</td>
</tr>
<tr>
<td><strong>Platelets (mil/mm³)</strong></td>
<td>260.4 (1009–37.1)</td>
<td>256.41 (1069–37.1)</td>
<td>245.6 (364–103)</td>
<td>0.66</td>
</tr>
<tr>
<td><strong>Albumin g/dl</strong></td>
<td>3.12 (4.9–1)</td>
<td>3.13 (4.9–1.1)</td>
<td>3.07 (4.5–1)</td>
<td>0.90</td>
</tr>
<tr>
<td><strong>Creatinine (mg/dl)</strong></td>
<td>1.52 (32–0.4)</td>
<td>1.64 (32–0.4)</td>
<td>1.18 (3.3–0.4)</td>
<td>0.91</td>
</tr>
</tbody>
</table>

**LOS**, length of stay; HIV/AIDS, human immunodeficiency virus infection/acquired immunodeficiency syndrome. LRT: Lower respiratory tract.
Microbiological and susceptibility testing

*Streptococcus pneumoniae* isolates were identified by standard procedures and characteristics, including Gram staining, negative catalase results, sensitivity to optochin, and bile solubility testing. Serotyping was performed using the Quellung reaction and serum from the Statens Serum Institut (Copenhagen, Denmark).

Susceptibility testing was performed by broth microdilution following the guidelines of the Clinical and Laboratory Standards Institute\(^9\). Susceptibility to penicillin, erythromycin, chloramphenicol, cefotaxime, trimethoprim/sulfamethoxazole, and vancomycin was tested. *S. pneumoniae ATCC 4919* was used as a control strain.

Statistical analysis

We used conventional dispersion methods for description and non-parametric tests for comparison of the data. The chi-squared test was used to compare dichotomous variables, and the Wilcoxon rank-sum test was used for linear variables. \( p \) values \( \leq 0.05 \) were considered to be significant. Analyses were conducted using SPSS software (version 18; SPSS Inc., Chicago, IL, USA).

Results

Isolates, study population, and clinical data

A total of 96 *S. pneumoniae* isolates with the patients’ clinical information were included in the study. Sites of isolation were non-invasive LRT secretions (CAP; \( n = 66 \)); other non-invasive clinical samples (\( n = 5 \)) and invasive specimens (\( n = 25 \)): blood (\( n = 12 \)), cerebrospinal fluid (\( n = 6 \)), ascites (\( n = 1 \)), pleural fluid (\( n = 5 \)), and brain abscess (\( n = 1 \)). The CAP group included more men (74.6%) than the invasive group (52%). The median patient age was 43 years (range, 18–94 years), and 66 (68.7%) patients were male.

The length of hospital stay ranged from 0 to 115 days (median, 10 days; Table 1). Head trauma was the most frequent comorbidity in patients with LRT *S. pneumoniae* (21.12%), and neoplasms were most frequent in patients with invasive strains (12%). Demographic and clinical characteristics are shown in Table 1.
Table 3  Distribution of pneumococcal serotypes isolated from invasive and non-invasive diseases by vaccine period in adult population in Mexico

<table>
<thead>
<tr>
<th>Pneumococcal serotypes</th>
<th>Total</th>
<th>Pre-PCV7 n = 18</th>
<th>Post-PCV7/PCV13 n = 78</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Invasive diseases</td>
<td>Non-invasive diseases</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>n</td>
<td>n</td>
<td>n</td>
</tr>
<tr>
<td>4</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>6A</td>
<td>3</td>
<td>3</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>6B</td>
<td>4</td>
<td>1</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>9V</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>19F</td>
<td>5</td>
<td>2</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>23F</td>
<td>7</td>
<td>2</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>11</td>
<td>1</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>19A</td>
<td>19</td>
<td>1</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>20</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>11A</td>
<td>4</td>
<td>3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>2</td>
<td>2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3B</td>
<td>1</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15A</td>
<td>4</td>
<td>1</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>15B</td>
<td>5</td>
<td>1</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>15C</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>16F</td>
<td>1</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17F</td>
<td>2</td>
<td>2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>18A</td>
<td>1</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>23A</td>
<td>4</td>
<td>1</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>23B</td>
<td>3</td>
<td>3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>24F</td>
<td>1</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>28A</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>6C</td>
<td>1</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>7C</td>
<td>2</td>
<td>2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9N</td>
<td>1</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>35B</td>
<td>1</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>N/T</td>
<td>4</td>
<td>1</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>96</td>
<td>4 (22.2%)</td>
<td>14 (77.7%)</td>
<td>20 (25.6%)</td>
</tr>
</tbody>
</table>

N/T = non-typable.
Value p = significance of pneumococcal disease by serotype between pre-PCV7 and post-PCV7/PCV13 period.

Serotypes and drug susceptibility

All pneumococcal isolates were serotyped with twenty-nine serotypes identified; 4 strains were considered non-typable. Serotype 19A was the most common serotype (19/19.8%), followed by serotypes 3 (11/11.4%) and 23F (7/7.3%).

We detected serotypes included in any of the four available vaccines (3, 4, 6B, 9V, 14, 19F, 23F, 19A, 9N, 11A, 15B, 17F, 20, 22F, and 35B) and 13 serotypes not included in any currently available vaccine (6C, 7C, 13, 15, 15A, 18A, 15C, 16F, 23A, 23B, 24F, 28A, and 38). We also detected serotype 6A, which is included in PCV13 but not in the polyvalent PPSV23 recommended for the adult population (Table 2). Serotypes 1, 5, 7F, 2, 8, 10A, 12F, and 18C, which are included in any of the PCV7, PCV10, PCV13, or PPSV23 vaccines, were not detected.

When examined by the pre- and post PCV7 periods, we found 18 pneumococcal isolates in the pre-PCV7 and 78 in the post-PCV7–PCV13 period. The circulation of PCV7 serotypes declined after 2008 (p < 0.0003), whereas no reduction was observed for the PCV13 serotypes. A slight but non-significant increase in the circulation of serotype 19A in the post-PCV7 period was detected (Table 2). There were 4 (22.2%) invasive pneumococcal infections in the pre-PCV7 period and 20 (25.6%) in the post-PCV7-PCV13 period compared to 14 (77.7%) and 58 (74.3%) non-invasive infections, respectively, as shown in Table 3. Isolates not included in any vaccine were only found in the post-PCV7-PCV13 period. No significant differences were found between serotypes causing invasive and non-invasive diseases as shown in Table 3, with serotypes 3 and 19A as the most frequent serotypes in both infections.

There were 6 pneumococcal meningitis cases reported in the post PCV7 period, and 3 of them showed resistance to penicillin. All of them were susceptible to cefotaxime. For non-meningitis isolates, an important reduction in
susceptibility to all antimicrobials except vancomycin (100% in all isolates) during the study period was observed (Table 4), particularly for erythromycin and TMP/SMX. Most of the increase in antimicrobial resistance was due to serotype 19A in the post-PCV7-PCV13 period (data not shown).

Discussion

In this study, we aimed to assess the risk factors and microbiological characteristics of CAP in adult patients from three tertiary teaching hospitals in Mexico over a period of 15 years. The most frequent comorbidity in patients with CAP S. pneumoniae was head trauma. This association is difficult to explain, as head trauma is viewed as a risk factor for infection with invasive isolates, rather than CAP isolates. The most frequent comorbidities in patients with non-respiratory strains were neoplasms, which is not surprising because invasive disease (sepsis) is caused by S. pneumoniae is a common complication of cancer.

Invasive pneumococcal disease is common in Latin America, and the effectiveness of PPSV23 in adult patients varies significantly. Thus, adequate information about circulating serotypes is crucial to define vaccination strategies and aid vaccine development. In this study, we analyzed S. pneumoniae serotype frequencies according to vaccine periods. The changes detected before and after PCV7 and PCV13 were smaller in these adults than in those reported for children, in whom increases in serotypes 19A and 7C and a dramatic reduction in serotype 19A after the introduction of PCV13 have been detected.

Theoretical serotype vaccine coverage for the pre-PCV7 and the post-PCV7-PCV13 periods were 55.5% and 12.8% for PCV7; 77.8% and 34.6% for PCV13 and 94.4% and 60.3% for PPS23 respectively.

The most prevalent serotype in this study during the period before the introduction of PCV7 was 23F, followed by serotypes 6B, 19A, and 19F. After the introduction of PCV7, the frequencies of serotypes 23F and 6B decreased, and serotypes 19A and 15B predominated. With the introduction of PCV13, serotype 19A continued to be predominant, followed by serotypes 3 and 23A. Although the prevalence of serotype 19A declined after the introduction of PCV13 in children, no such effect was observed in the adults in this study; on the contrary, the frequency of this serotype increased slightly.

Even with the recent changes in dosing regimens for PCV10, an epidemiological impact is apparent in adults, with a reduction in PCV7 serotypes after 2008. In the current study, we detected no reduction in PCV13 or PPSv23 serotypes. This finding has also been reported for the Japanese population.

After the introduction of PCV7 for children under 2 years, there has been a decrease in the transmission of the included serotypes to adults. This could be due to a herd effect but cannot be concluded with certainty. Serotypes 3 and 19A have low immunogenicity (PCV13), so they do not manage to generate a decrease in colonization of vaccinated children, so they continue to be transmitted to adults. It underscores the need for surveillance of specific populations, particularly adults (including those with CAP), because this population may be a reservoir for different serotypes and the effects seen in children do not reflect protection of older and susceptible community members.

In one of the largest and most recent studies of the antimicrobial susceptibility of S. pneumoniae conducted in Latin America, 182 S. pneumoniae isolates were found to be predominantly non-susceptible to penicillin (51.6%), with the highest rates of resistance observed in Mexico (84.8%) and Venezuela (81.2%). Similarly, elevated non-susceptibility rates for ceftriaxone were detected in both

Table 4 Drug susceptibility of S. pneumoniae throughout the study period

<table>
<thead>
<tr>
<th>Vaccine period</th>
<th>PEN meningitis (n = 6)</th>
<th>PEN Non-meningitis (n = 90)</th>
<th>CTX meningitis (n = 6)</th>
<th>CTX Non-meningitis (n = 90)</th>
<th>ERY (n = 96)</th>
<th>CHL (n = 96)</th>
<th>TMP/SMX (n = 96)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pre-PCV7 (n = 18) S, n (%)</td>
<td>0 (0)</td>
<td>15 (16.6)</td>
<td>0 (0)</td>
<td>15 (16.6)</td>
<td>14 (14.6)</td>
<td>17 (17.7)</td>
<td>7 (7.3)</td>
</tr>
<tr>
<td>I, n (%)</td>
<td>0 (0)</td>
<td>1 (1.1)</td>
<td>0 (0)</td>
<td>1 (1.1)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Resistant, n (%)</td>
<td>0 (0)</td>
<td>2 (2.2)</td>
<td>0 (0)</td>
<td>2 (2.2)</td>
<td>4 (4.2)</td>
<td>1 (1.0)</td>
<td>11 (11.5)</td>
</tr>
<tr>
<td>Post-PCV7 (n = 78) S, n (%)</td>
<td>3 (50.0)</td>
<td>43 (4.5)</td>
<td>6 (100)</td>
<td>41 (45.5)</td>
<td>49 (51.0)</td>
<td>58 (60.4)</td>
<td>19 (19.8)</td>
</tr>
<tr>
<td>I, n (%)</td>
<td>0 (0)</td>
<td>20 (22.2)</td>
<td>0 (0)</td>
<td>18 (20.0)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>15 (15.6)</td>
</tr>
<tr>
<td>R, n (%)</td>
<td>3 (50.0)</td>
<td>9 (10.0)</td>
<td>0 (0)</td>
<td>13 (14.4)</td>
<td>29 (30.2)</td>
<td>20 (20.8)</td>
<td>44 (45.8)</td>
</tr>
<tr>
<td>p</td>
<td>1.00</td>
<td>0.16</td>
<td>1.00</td>
<td>0.09</td>
<td>0.28</td>
<td>0.10</td>
<td>0.24</td>
</tr>
</tbody>
</table>

The following breakpoints were used for the interpretation of penicillin susceptibility. For non-meningeal cases: S: susceptible, S: ≤2 mg/l; I: 4 mg/l; and R: ≥8 mg/l. For meningeval cases: S: ≤0.06 mg/l, and R: ≥0.12 mg/l. The following breakpoints were used for cefotaxime. For non-meningeal cases: S: ≤1 mg/l; I: 2 mg/l; and R: ≥4 mg/l. For meningeval cases: S: ≤0.5 mg/l; I: 1 mg/l; and R: ≥2 mg/l.

S: susceptible, I: intermediate; R: resistant; PEN: Penicillin; CTX: cefotaxime; ERY: erythromycin; CHL: chloramphenicol; TMP/SXT, trimethoprim/sulfamethoxazole. All isolates were susceptible to vancomycin.

Value p represents significance in decreased susceptibility.
countries (21.1–43.7%)\textsuperscript{12}. We identified a notable increase in non-susceptibility to penicillin in our isolates and a steady decrease in susceptibility to cephalosporins; both changes are much greater than previously reported\textsuperscript{8}.

For community meningitis in our population, cefotaxime or ceftriaxone plus vancomycin are used. For NAC, levofloxacin or ceftriaxone plus a macrolide are used. If there is suspicion of penicillin-resistant \textit{S. pneumoniae}, then vancomycin is added.

Lower susceptibility to trimethoprim/sulfamethoxazole and similar susceptibility to erythromycin have been found in isolates collected from children\textsuperscript{1}.

This study has several limitations. As we were not able to document the patients’ immunization status, the influence of vaccination on the selection of individual serotypes remains unclear. In addition, we included sputum samples, which are practical, but imperfect, specimens for the microbiological investigation of CAP. Microscopic examination of sputum quality was performed for all samples, and only mucopurulent material was tested. Nevertheless, sputum is always at risk of contamination with oropharyngeal microbiota. Despite these limitations, national guidelines recommend sputum investigation for patients admitted to hospital with moderate to severe CAP, to aid microbiological diagnosis\textsuperscript{13}.

In this study, more patients with CAP than with invasive disease were male, and head trauma was the most common comorbidity in the CAP group. The most prevalent serotype was 19A, and the proportion of PCV7 serotypes declined after 2008; no reduction in PCV13 serotypes was observed. Decreased susceptibility to most antimicrobials tested was observed. Our results underscore the need for surveillance of the adult population to aid in the control of diseases associated with \textit{S. pneumoniae}.

\section*{Conflict of interest}

The authors declare that they have no conflicts of interest.

\section*{References}


